Phase III Data And GMP Nod Bring Prestige’s Trastuzumab Closer To Launch

Latest Developments Bode Well For Tuznue Biosimilar Rival To Herceptin

 
• By Dave Wallace

Prestige BioPharma says its proposed Tuznue trastuzumab rival to Herceptin is moving closer to launch in global markets, after reporting positive Phase III data for the biosimilar as well as a European GMP certification for its manufacturing facility in Korea.

Double Six Red Dice Good Luck
Two positive developments will allow Prestige to move forward • Source: Stocksolutions / Alamy Stock Photo

Prestige Biopharma has marked two more milestones in the journey to bringing its HD201 proposed trastuzumab biosimilar rival to Herceptin to international markets, with positive Phase III data and a European good manufacturing practice certification bringing the Singapore-based firm “one step closer to global launch of Tuznue.”

Announcing positive efficacy and safety results from its “TROIKA” Phase III study for HD201, Prestige said the study met its primary endpoint and showed equivalent efficacy and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products